The CD44+/CD24- phenotype is enriched in basal-like breast tumors.

Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics.

CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis.

Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype.

Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis.

Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers.

CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis.

Molecular definition of breast tumor heterogeneity.

Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy.

The clinicopathologic and prognostic significance of CD44+/CD24(-/low) and CD44-/CD24+ tumor cells in invasive breast carcinomas.

Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers.

Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer.

Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma.

Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas.

Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy.

Tissue-specific promoters active in CD44+CD24-/low breast cancer cells.

The prognostic role of a gene signature from tumorigenic breast-cancer cells.

Isolation and biological analysis of tumor stem cells from pancreatic adenocarcinoma.

Oncolytic adenoviruses kill breast cancer initiating CD44+CD24-/low cells.

Molecular analysis reveals heterogeneity of mouse mammary tumors conditionally mutant for Brca1.